ArticleChina CDC weekly2023
Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023.
Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 100 citations in OpenAlex.
- Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.Human vaccines & immunotherapeutics · 2025Trial
- Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China.Nature communications · 2025Trial
- Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population.Frontiers in immunology · 2025Trial
- Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.Emerging microbes & infections · 2024Trial
- Enhancing the psychological well-being and sleep quality of healthcare providers with a multimodal psychological support program: a randomized controlled trial.Frontiers in public health · 2024Trial
- Cognitive function among COVID-19 survivors in the subacute phase during the epidemic of Omicron variant in China.Journal of Zhejiang University. Science. B · 2026Article
- Optimizing COVID-19 vaccination for older adults: superior efficacy of heterologous regimens in reducing infection and mortality rates among patients aged 80 years and older during the Omicron BA.5/BF.7 outbreak.BMC infectious diseases · 2026Article
- A comparative analysis of fetal mirror-image dextrocardia in China pre- and post-COVID-19 lockdown lifting.BMC pregnancy and childbirth · 2026Article
- Article
- Multicentre development and two-stage validation of a patient-reported outcome measure for chronic obstructive pulmonary disease.iScience · 2026Article
- Rehabilitation status and preference for medical choice behaviours of long COVID-19 in China: a national cross-sectional study and discrete choice experiment.Journal of global health · 2026Article
- Post-COVID-19 surge in Guillain-Barré syndrome during the Omicron wave in China with clinical characteristics and potential immune-mediated pathways.Scientific reports · 2026Article
- Pathogen landscape and synergistic interactions in pediatric ARIs: implications for broad-spectrum surveillance via targeted NGS.Microbiology spectrum · 2026Article
- Humoral immunity and infection status of PLWH following vaccination after the BA.5/BF.7 wave.Frontiers in microbiology · 2026Article
- Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity.BMC medicine · 2025Article
- WSK-V102C COVID-19 vaccine effectiveness against SARS-CoV-2 JN.1 symptomatic infection among adults 60 years and older: a prospective observational cohort study in Shaanxi Province, China, 2024.BMC public health · 2025Observational
- China's post-zero-COVID Omicron wave: A Bayesian analysis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The potential of wastewater monitoring as a novel surveillance tool for early warning ofEmerging microbes & infections · 2025Article
- Attitudes towards vaccination against COVID-19 during pregnancy and its determinants among people of reproductive age.Human vaccines & immunotherapeutics · 2025Article
- Humoral immunity and clinical characteristics of Chinese college students experiencing a BA.5/BF.7 and XBB.1.5 wave.Scientific reports · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: A considerable percentage of the population has received both primary and booster vaccinations, which could potentially provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections and related symptoms. What is added by this report?: The self-reported infection rate, as determined from an online survey, reached its peak (15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in China being infected as of February 7, 2023. During the epidemic, the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0% within three months of vaccination and 37.9% between 3 and 6 months following vaccination. Furthermore, the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7% to 83.2% within three months and from 25.9% to 69.0% between 3 and 6 months post-booster vaccination. What are the implications for public health practice?: The development and production of efficacious vaccines, together with prompt vaccinations or emergency vaccinations, have the potential to mitigate the epidemic's impact and safeguard public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.